Member of the European Parliament · Italy ECR
Carlo Ciccioli
MEP for Italy · European Conservatives & Reformists · FRATELLI D' ITALIA · official EP profile
As of 12 September 2026, Carlo Ciccioli (ECR, Italy) has declared 8 lobby meetings this term - rank 579 of 719 MEPs by declared meetings.
That is one of the lighter declaration records in the Parliament - against an average of 85 meetings per MEP, and 62 of 81 within European Conservatives & Reformists.
90% of this MEP's declared counterpart entries, including diplomatic and government entries, carry a declared EU Transparency Register link - above the like-for-like raw Parliament-wide share of 51%.
Compare with the rest: search and sort all 719 MEPs, or see every MEP from Italy.
Compared with the averages
Transparency this term
Monthly declared meetings (bars) and the share of all counterpart entries carrying a declared Register link, including diplomatic and government entries (line), July 2024 to September 2026. This is the same current-term window as the figures above, beginning 16 July 2024.
Current month, partial through 11 Sep 2026: 0 declared meetings in Sep 2026. Peak: 2 in Apr 2026.
Busiest month: 2 declared in April 2026. Months with no declared meetings have no Register-share value.
Who Carlo Ciccioli meets most
| Declared counterpart | Meetings |
|---|---|
| AstraZeneca PLC | 2 |
| Bristol-Myers Squibb Company | 1 |
| Regeneron Pharmaceuticals Inc. | 1 |
| Cattaneo Zanetto Pomposo & Co. | 1 |
| Ferrovie dello Stato Italiane S.p.A | 1 |
Counterparts are merged by resolved Transparency Register identity where possible. An entry counts as register-linked above only when the MEP declaration itself carries a Register link.
Where the meetings cluster
Most-met sectors
Health & pharma (7), Public affairs & consultancy (1), Transport & automotive (1)
Meetings by committee topic
Industry, Research and Energy (7), Transport and Tourism (1)
Most recent declared meetings
| Date | Counterpart | Capacity | Subject |
|---|---|---|---|
| 1 Jul 2026 | Novo Nordisk A/S ↗ | Shadow rapporteur | Biotech Act |
| 30 Jun 2026 | Regeneron Pharmaceuticals Inc.; Johnson & Johnson ↗ | Shadow rapporteur | Biotech Act |
| 25 Jun 2026 | AstraZeneca PLC ↗ | Shadow rapporteur | Biotech Act |
| 22 Apr 2026 | AstraZeneca PLC ↗ | Shadow rapporteur | Biotech act |
| 14 Apr 2026 | Amgen Inc ↗ | Shadow rapporteur | Biotech act |
| 26 Mar 2026 | European Federation of Pharmaceutical Industries and Associations ↗ | Shadow rapporteur | Biotech act |
| 24 Feb 2026 | Cattaneo Zanetto Pomposo & Co. ↗; Bristol-Myers Squibb Company ↗ | Shadow rapporteur | Biotech act |
| 22 Oct 2025 | FERROVIE DELLO STATO ITALIANE S.p.A. ↗ | Member | CEF and military mobility |
The full record is in the official EP declarations.
Roll-call voting record
Recorded votes only. Parliament held 5,568 roll-call votes while Carlo Ciccioli held the seat, 537 of them the final vote on a text. A member with no vote recorded may have been on parliamentary business, ill, on leave, or present without voting - the published record does not distinguish these and gives no reason. Votes taken by show of hands or by secret ballot are not recorded by name and are absent here.
How they voted on final texts
Share of the 537 final votes held while seated.
With and against the group
On the 422 final texts where more than half of ECR members casting a vote went one way, and Carlo Ciccioli also voted. Groups are not bound to vote together: a Member's mandate is personal and exercised freely, so neither figure is a measure of performance.
Final texts where Carlo Ciccioli differed from the ECR majority
| Date | Text | Their vote | ECR majority |
|---|---|---|---|
| 9 July 2026 | RC-B10-0357/2026 – Motion for a resolution (as a whole) | Abstained | For |
| 8 July 2026 | A10-0163/2026 – Tonino Picula – Motion for a resolution (as a whole) | Abstained | For |
| 7 July 2026 | A10-0169/2026 – Matthias Ecke – Motion for a resolution (as a whole) | Abstained | Against |
| 17 June 2026 | A10-0140/2026 – Rasa Juknevičienė – Motion for a resolution (as a whole) | Abstained | For |
| 17 June 2026 | A10-0146/2026 – Karin Karlsbro – Motion for a resolution | For | Abstained |
| 16 June 2026 | A10-0147/2026 – Lukas Mandl – Motion for a resolution (as a whole) | Abstained | Against |
| 30 April 2026 | A10-0058/2026 – Elżbieta Katarzyna Łukacijewska – Motion for a resolution (as a whole) | Abstained | Against |
| 29 April 2026 | A10-0098/2026 – Danuše Nerudová – Commission proposal | Abstained | Against |
| 29 April 2026 | A10-0057/2026 – Pasquale Tridico – Motion for a resolution (as a whole) | Abstained | For |
| 29 April 2026 | A10-0052/2026 – Pasquale Tridico – Motion for a resolution (as a whole) | Abstained | For |
14 further instances are not listed. All roll-call votes.
Unlinked but matchable
1 counterpart entry in Carlo Ciccioli's declarations appears to match an EU Transparency Register entry without being linked in the declaration:
- “Regeneron Pharmaceuticals Inc.” - likely Regeneron Pharmaceuticals Inc. (1 counterpart entry)
Matching is automated and can be wrong - see how matching works. Linking the register entry is the fix, and it is the MEP office's to make.